RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Torii Pharmaceutical Co Stock

Torii Pharmaceutical Co Stocks 2024

Torii Pharmaceutical Co Stocks

28.1 M

Ticker

4551.T

ISIN

JP3635800000

WKN

887536

In 2024, Torii Pharmaceutical Co had 28.1 M outstanding stocks, a 0% change from the 28.1 M stocks in the previous year.

The Torii Pharmaceutical Co Stocks history

YEARNUMBER OF STOCKS (undefined JPY)
2026e28.1
2025e28.1
2024e28.1
202328.1
202228.1
202128.09
202028.08
201928.07
201828.06
201728.98
201628.28
201528.3
201428
201328
201228
201128
201028
200928
200828
200728
200628
200528
200428

Torii Pharmaceutical Co shares outstanding

The number of shares was Torii Pharmaceutical Co in 2023 — This indicates how many shares 28.103 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Torii Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Torii Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Torii Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Torii Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Torii Pharmaceutical Co Aktienanalyse

What does Torii Pharmaceutical Co do?

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people. Torii Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Torii Pharmaceutical Co's Shares Outstanding

Torii Pharmaceutical Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Torii Pharmaceutical Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Torii Pharmaceutical Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Torii Pharmaceutical Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Torii Pharmaceutical Co stock

How many stocks are there of Torii Pharmaceutical Co?

The current number of stocks of Torii Pharmaceutical Co is 28.1 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Torii Pharmaceutical Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Torii Pharmaceutical Co evolved in recent years?

The number of shares of Torii Pharmaceutical Co has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Torii Pharmaceutical Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Torii Pharmaceutical Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Torii Pharmaceutical Co pay?

Over the past 12 months, Torii Pharmaceutical Co paid a dividend of 120 JPY . This corresponds to a dividend yield of about 3.24 %. For the coming 12 months, Torii Pharmaceutical Co is expected to pay a dividend of 121.66 JPY.

What is the dividend yield of Torii Pharmaceutical Co?

The current dividend yield of Torii Pharmaceutical Co is 3.24 %.

When does Torii Pharmaceutical Co pay dividends?

Torii Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Torii Pharmaceutical Co?

Torii Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Torii Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 121.66 JPY are expected. This corresponds to a dividend yield of 3.29 %.

In which sector is Torii Pharmaceutical Co located?

Torii Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Torii Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Torii Pharmaceutical Co from 3/1/2025 amounting to 60 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Torii Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Torii Pharmaceutical Co in the year 2023?

In the year 2023, Torii Pharmaceutical Co distributed 100 JPY as dividends.

In which currency does Torii Pharmaceutical Co pay out the dividend?

The dividends of Torii Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Torii Pharmaceutical Co

Our stock analysis for Torii Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.